A number of additional immune checkpoints have been prime targets for therapeutic investigation, including CTLA-4, PD-L2, LAG-3, TIM-3, and TIGIT, which are upregulated in ccRCC [104]. This evidence concerns the gene PDCD1LG2 and nonpapillary renal cell carcinoma.